Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New toothpaste aims to zap tooth pain in major trial

NCT ID NCT07215767

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 26, 2026 · Updated 2 times

Summary

This study tests a new toothpaste designed to reduce tooth sensitivity. About 850 people with sensitive teeth will brush twice daily for 8 weeks. Researchers will measure pain from air puffs and gentle touch to see if the new formula works better than other toothpastes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

688 people

The number who actually took part.

Started

Sep 2025

Finished

Aug 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Provision of signed and dated informed consent document (and assent document, if appropriate) * Participant is biologically male or female. * Participant is 12 to 65 years of age, inclusive, at the time of signing the consent/assent form. * Participant is in good general, oral and mental health with, in the opinion of the investigator or medically qualified designee, no clinically significant or relevant abnormalities in self-reported medical history, or upon oral examination, that would impact their safety or well-being, or the outcomes of the study, if they were to participate in the study, or affect their ability to understand and follow study requirements. * Participant has a history of tooth sensitivity lasting more than six months but not more than 10 years (self-reported). * Participant has a minimum of 2 non-adjacent teeth (incisors, canines or premolars), in different quadrants, with exposed dentin due to facial/cervical erosion, abrasion or gingival recession, and clinically confirmed dentin hypersensitivity to tactile and evaporative (air) stimuli at Screening and Baseline. Exclusion Criteria: * Female participant who is pregnant at Screening and Baseline, or is intending to become pregnant during the study. * Female participant who is breastfeeding. * Participant with known or suspected intolerance or hypersensitivity to any of the study products, any of their stated ingredients or closely related compounds. * Participant is participating in, or has participated in, other studies (including non-medicinal studies) involving an Investigational Product within 30 days of Screening or plans to participate in other studies (including non-medicinal studies) during this study. * Participant has participated in a tooth sensitivity study within 8 weeks of Screening. * Participant is currently using an oral care product indicated for dentin hypersensitivity relief or care of sensitive teeth or has used an antihypersensitivity oral care product within 8 weeks of Screening. * Participant takes daily doses of medications/treatments which, in the opinion of the investigator or medically qualified designee, could interfere with their perception of tooth sensitivity. * Participant has had professional tooth de-sensitising treatment within 8 weeks of Screening. * Participant has had a tooth bleaching procedure within 8 weeks of Screening. * Participant has had dental prophylaxis within 4 weeks of Screening. * Participant with evidence of gross intra-oral neglect or the need for extensive dental therapy. * Participant with evidence of current/recent active dental caries or treatment for decay within 12 months of Screening. * Participant who, in the opinion of the investigator or dentally qualified designee, is at high risk of dental caries. * Participant with specific dentition exclusions for 'Test Teeth'. * Participant has taken antibiotics in the 2 weeks prior to Screening or Baseline.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dentin hypersensitivity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • All Sum Research Limited

    Melbourne, Florida, 32935, United States

  • Salus Research, Inc.

    Fort Wayne, Indiana, 46825, United States

  • Silverstone Research

    Las Vegas, Nevada, 89146, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.